JP2019077725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019077725A5 JP2019077725A5 JP2019017086A JP2019017086A JP2019077725A5 JP 2019077725 A5 JP2019077725 A5 JP 2019077725A5 JP 2019017086 A JP2019017086 A JP 2019017086A JP 2019017086 A JP2019017086 A JP 2019017086A JP 2019077725 A5 JP2019077725 A5 JP 2019077725A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- ethyl
- azaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- HZMNRFTWMDFPNO-UHFFFAOYSA-N ethyl 2-(4-pyrazol-1-ylpiperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate Chemical compound N1(N=CC=C1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC HZMNRFTWMDFPNO-UHFFFAOYSA-N 0.000 claims 1
- HEJAEKBVOZHTRA-UHFFFAOYSA-N ethyl 2-[4-(2-methylpyrazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound CN1N=CC=C1C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC HEJAEKBVOZHTRA-UHFFFAOYSA-N 0.000 claims 1
- QZVYLGBTRSXKIE-UHFFFAOYSA-N ethyl 2-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound O=C1N(CCC1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC QZVYLGBTRSXKIE-UHFFFAOYSA-N 0.000 claims 1
- QKTXQEYKBXLLNQ-TVRKMHQQSA-N ethyl 2-[4-[(2R)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound FC1(C[C@@H](N(C1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC)CO)F QKTXQEYKBXLLNQ-TVRKMHQQSA-N 0.000 claims 1
- BOEACPBYTRPLBC-UORCXSCMSA-N ethyl 2-[4-[(2R,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound F[C@@H]1C[C@@H](N(C1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC)CO BOEACPBYTRPLBC-UORCXSCMSA-N 0.000 claims 1
- BOEACPBYTRPLBC-JQZVFVSYSA-N ethyl 2-[4-[(2R,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound F[C@H]1C[C@@H](N(C1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC)CO BOEACPBYTRPLBC-JQZVFVSYSA-N 0.000 claims 1
- XBYWKKNGSJNKJG-JJXOGSGTSA-N ethyl 2-[4-[(2R,4S)-4-fluoro-2-methoxycarbonylpyrrolidin-1-yl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound F[C@H]1C[C@@H](N(C1)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC)C(=O)OC XBYWKKNGSJNKJG-JJXOGSGTSA-N 0.000 claims 1
- IKKKUWUFDRRBSC-AFJQURTJSA-N ethyl 2-[4-[(2S)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate Chemical compound C(C)[C@@H]1N(C(CC1)=O)C1CCN(CC1)C1CC2(C1)CN(CC2)C(=O)OCC IKKKUWUFDRRBSC-AFJQURTJSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- -1 hydroxy, methoxy, methyl Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 0 C*(C)C(CCC1)N1C(C(F)(F)F)=O Chemical compound C*(C)C(CCC1)N1C(C(F)(F)F)=O 0.000 description 17
- ZAVNAIXXOHWBDG-UHFFFAOYSA-N CC(CCC1)N1C(CC(F)(F)F)=O Chemical compound CC(CCC1)N1C(CC(F)(F)F)=O ZAVNAIXXOHWBDG-UHFFFAOYSA-N 0.000 description 1
- YQSRKFAOUYPUAC-UHFFFAOYSA-N CC(CCC1)N1C(CCN)=O Chemical compound CC(CCC1)N1C(CCN)=O YQSRKFAOUYPUAC-UHFFFAOYSA-N 0.000 description 1
- FMOMSFCVAGTHGO-UHFFFAOYSA-N CC(CCC1)N1C(COC)=O Chemical compound CC(CCC1)N1C(COC)=O FMOMSFCVAGTHGO-UHFFFAOYSA-N 0.000 description 1
- VXQOOMPIHVLABQ-UHFFFAOYSA-N CC(CCC1)N1C(NC1CCC1)=O Chemical compound CC(CCC1)N1C(NC1CCC1)=O VXQOOMPIHVLABQ-UHFFFAOYSA-N 0.000 description 1
- PJVFUINVNVDZBV-UHFFFAOYSA-N CC(CCC1)N1C(OC1CCC1)=O Chemical compound CC(CCC1)N1C(OC1CCC1)=O PJVFUINVNVDZBV-UHFFFAOYSA-N 0.000 description 1
- GBKJBXGCDXMHPY-UHFFFAOYSA-N CC1N(COCCN(C)C)CCC1 Chemical compound CC1N(COCCN(C)C)CCC1 GBKJBXGCDXMHPY-UHFFFAOYSA-N 0.000 description 1
- LCXFKHBYVGVYGH-UHFFFAOYSA-N CCC(CCC1)N1C(C1CC1)=O Chemical compound CCC(CCC1)N1C(C1CC1)=O LCXFKHBYVGVYGH-UHFFFAOYSA-N 0.000 description 1
- UZOZSUUBKDDEPD-MLWJPKLSSA-N CCC(N(C1)C(C)C[C@@H]1F)=O Chemical compound CCC(N(C1)C(C)C[C@@H]1F)=O UZOZSUUBKDDEPD-MLWJPKLSSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402013.5A GB201402013D0 (en) | 2014-02-06 | 2014-02-06 | Pharmaceutical compounds |
| GB1402013.5 | 2014-02-06 | ||
| GB1416622.7 | 2014-09-19 | ||
| GBGB1416622.7A GB201416622D0 (en) | 2014-09-19 | 2014-09-19 | Pharmaceutical compounds |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550483A Division JP6479029B2 (ja) | 2014-02-06 | 2015-02-06 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168341A Division JP2021006571A (ja) | 2014-02-06 | 2020-10-05 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019077725A JP2019077725A (ja) | 2019-05-23 |
| JP2019077725A5 true JP2019077725A5 (https=) | 2019-09-26 |
| JP6774513B2 JP6774513B2 (ja) | 2020-10-28 |
Family
ID=52465550
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550483A Active JP6479029B2 (ja) | 2014-02-06 | 2015-02-06 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2019017086A Active JP6774513B2 (ja) | 2014-02-06 | 2019-02-01 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2020168341A Withdrawn JP2021006571A (ja) | 2014-02-06 | 2020-10-05 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023060030A Active JP7652829B2 (ja) | 2014-02-06 | 2023-04-03 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023076025A Active JP7652833B2 (ja) | 2014-02-06 | 2023-05-02 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023076024A Active JP7652832B2 (ja) | 2014-02-06 | 2023-05-02 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2025041135A Pending JP2025085736A (ja) | 2014-02-06 | 2025-03-14 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550483A Active JP6479029B2 (ja) | 2014-02-06 | 2015-02-06 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020168341A Withdrawn JP2021006571A (ja) | 2014-02-06 | 2020-10-05 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023060030A Active JP7652829B2 (ja) | 2014-02-06 | 2023-04-03 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023076025A Active JP7652833B2 (ja) | 2014-02-06 | 2023-05-02 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2023076024A Active JP7652832B2 (ja) | 2014-02-06 | 2023-05-02 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| JP2025041135A Pending JP2025085736A (ja) | 2014-02-06 | 2025-03-14 | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9670183B2 (https=) |
| EP (4) | EP4714446A2 (https=) |
| JP (7) | JP6479029B2 (https=) |
| KR (1) | KR102352388B1 (https=) |
| CN (2) | CN109851610B (https=) |
| AU (3) | AU2015213900B2 (https=) |
| BR (1) | BR112016017979B1 (https=) |
| CA (1) | CA2938169C (https=) |
| CL (1) | CL2016001983A1 (https=) |
| CY (1) | CY1120834T1 (https=) |
| DK (2) | DK3102568T3 (https=) |
| ES (2) | ES2688548T3 (https=) |
| FI (1) | FI3406609T3 (https=) |
| HR (2) | HRP20181499T1 (https=) |
| HU (1) | HUE068301T2 (https=) |
| IL (1) | IL247117B (https=) |
| LT (2) | LT3406609T (https=) |
| MX (2) | MX371529B (https=) |
| NZ (1) | NZ723103A (https=) |
| PH (1) | PH12016501570B1 (https=) |
| PL (2) | PL3102568T3 (https=) |
| PT (2) | PT3102568T (https=) |
| RS (2) | RS65894B1 (https=) |
| RU (1) | RU2685230C2 (https=) |
| SA (1) | SA516371614B1 (https=) |
| SG (1) | SG11201606269WA (https=) |
| SI (2) | SI3102568T1 (https=) |
| SM (1) | SMT202400446T1 (https=) |
| UA (1) | UA122121C2 (https=) |
| WO (1) | WO2015118342A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
| KR102352388B1 (ko) * | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물 |
| GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| US10329289B2 (en) | 2015-12-23 | 2019-06-25 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor |
| WO2018002760A1 (en) * | 2016-07-01 | 2018-01-04 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JP7134173B2 (ja) | 2017-06-21 | 2022-09-09 | 第一三共株式会社 | Ｅｐ３００／ｃｒｅｂｂｐ阻害剤 |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7166331B2 (ja) * | 2017-08-01 | 2022-11-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 中間体化合物及び方法 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| EP4219464A1 (en) | 2018-03-23 | 2023-08-02 | Pfizer Inc. | Piperazine azaspiro derivaves |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PE20221454A1 (es) * | 2019-10-09 | 2022-09-21 | Novartis Ag | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |
| KR20220079921A (ko) * | 2019-10-09 | 2022-06-14 | 노파르티스 아게 | M4 작용제로서의 2-아자스피로[3.4]옥탄 유도체 |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| EP4100410B1 (en) * | 2020-02-05 | 2026-04-22 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| US11912705B2 (en) * | 2020-08-20 | 2024-02-27 | The Corporation Of Mercer University | Cathinone derivatives, pharmaceutical formulations, and methods |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| DK4508045T3 (da) | 2022-08-04 | 2025-10-20 | Nxera Pharma Uk Ltd | Citratsalt-former af en muskarinreceptor-agonist |
| KR20250086639A (ko) * | 2022-09-16 | 2025-06-13 | 세레벨 쎄라퓨틱스, 엘엘씨 | M4 활성제/조절제 및 이의 용도 |
| EP4649077A1 (en) * | 2023-01-12 | 2025-11-19 | Cerevel Therapeutics, LLC | Spiro derivatives as m4 activators/modulators and uses thereof |
| JP2026503599A (ja) * | 2023-01-24 | 2026-01-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 重水素化化合物 |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| WO2025030095A1 (en) | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
| WO2026050238A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
| WO2026050229A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050231A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a bipolar disorder |
| WO2026050225A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050278A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| JPWO2002085890A1 (ja) * | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2006105035A2 (en) * | 2005-03-28 | 2006-10-05 | Vertex Pharmaceuticals Incorporated | Muscarinic modulators |
| US7858635B2 (en) | 2005-12-22 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Spiro compounds as modulators of muscarinic receptors |
| CN101426499A (zh) | 2006-02-22 | 2009-05-06 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| NZ570497A (en) * | 2006-02-22 | 2011-09-30 | Vertex Pharma | Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors |
| BRPI0708524A2 (pt) * | 2006-03-03 | 2011-05-31 | Novartis Ag | compostos de n-formil hidroxilamina |
| GB0706188D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| US8119661B2 (en) * | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| JP2012506883A (ja) | 2008-10-29 | 2012-03-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換されたスピロアミン |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2012020813A1 (ja) * | 2010-08-10 | 2012-02-16 | 大日本住友製薬株式会社 | 縮環ピロリジン誘導体 |
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| BR112015006029B1 (pt) * | 2012-09-18 | 2022-01-25 | Heptares Therapeutics Limited | Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias |
| EP2991980B1 (en) | 2013-04-30 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| KR102352388B1 (ko) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물 |
| JP6581100B2 (ja) | 2014-02-06 | 2019-09-25 | リボサイエンス・エルエルシー | インフルエンザｒｎａ複製の阻害剤としての４’−ジフルオロメチル置換ヌクレオシド誘導体 |
| MA39484A (fr) | 2014-09-19 | 2016-03-24 | Bayer Pharma AG | Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1 |
| WO2016044789A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| EA033697B1 (ru) | 2014-09-19 | 2019-11-18 | Glaxosmithkline Ip Dev Ltd | Активаторы растворимой гуанилатциклазы и их применение |
-
2015
- 2015-02-06 KR KR1020167024572A patent/KR102352388B1/ko active Active
- 2015-02-06 HU HUE18179258A patent/HUE068301T2/hu unknown
- 2015-02-06 EP EP26156152.6A patent/EP4714446A2/en active Pending
- 2015-02-06 US US15/117,018 patent/US9670183B2/en active Active
- 2015-02-06 PT PT15703826T patent/PT3102568T/pt unknown
- 2015-02-06 HR HRP20181499TT patent/HRP20181499T1/hr unknown
- 2015-02-06 MX MX2016010322A patent/MX371529B/es active IP Right Grant
- 2015-02-06 PL PL15703826T patent/PL3102568T3/pl unknown
- 2015-02-06 EP EP15703826.6A patent/EP3102568B1/en active Active
- 2015-02-06 UA UAA201609185A patent/UA122121C2/uk unknown
- 2015-02-06 JP JP2016550483A patent/JP6479029B2/ja active Active
- 2015-02-06 ES ES15703826.6T patent/ES2688548T3/es active Active
- 2015-02-06 AU AU2015213900A patent/AU2015213900B2/en active Active
- 2015-02-06 LT LTEP18179258.1T patent/LT3406609T/lt unknown
- 2015-02-06 SI SI201530399T patent/SI3102568T1/sl unknown
- 2015-02-06 PL PL18179258.1T patent/PL3406609T3/pl unknown
- 2015-02-06 CN CN201910003375.6A patent/CN109851610B/zh active Active
- 2015-02-06 DK DK15703826.6T patent/DK3102568T3/en active
- 2015-02-06 SM SM20240446T patent/SMT202400446T1/it unknown
- 2015-02-06 DK DK18179258.1T patent/DK3406609T3/da active
- 2015-02-06 RU RU2016133684A patent/RU2685230C2/ru active
- 2015-02-06 SI SI201532034T patent/SI3406609T1/sl unknown
- 2015-02-06 EP EP18179258.1A patent/EP3406609B1/en active Active
- 2015-02-06 HR HRP20241145TT patent/HRP20241145T1/hr unknown
- 2015-02-06 BR BR112016017979-0A patent/BR112016017979B1/pt active IP Right Grant
- 2015-02-06 WO PCT/GB2015/050331 patent/WO2015118342A1/en not_active Ceased
- 2015-02-06 CA CA2938169A patent/CA2938169C/en active Active
- 2015-02-06 NZ NZ723103A patent/NZ723103A/en unknown
- 2015-02-06 PT PT181792581T patent/PT3406609T/pt unknown
- 2015-02-06 CN CN201580017993.6A patent/CN106458986B/zh active Active
- 2015-02-06 LT LTEP15703826.6T patent/LT3102568T/lt unknown
- 2015-02-06 EP EP24177415.7A patent/EP4413985A3/en active Pending
- 2015-02-06 RS RS20240960A patent/RS65894B1/sr unknown
- 2015-02-06 SG SG11201606269WA patent/SG11201606269WA/en unknown
- 2015-02-06 ES ES18179258T patent/ES2986327T3/es active Active
- 2015-02-06 RS RS20181127A patent/RS57843B1/sr unknown
- 2015-02-06 FI FIEP18179258.1T patent/FI3406609T3/fi active
- 2015-02-06 MX MX2020001236A patent/MX393637B/es unknown
-
2016
- 2016-08-04 SA SA516371614A patent/SA516371614B1/ar unknown
- 2016-08-04 IL IL247117A patent/IL247117B/en active IP Right Grant
- 2016-08-05 CL CL2016001983A patent/CL2016001983A1/es unknown
- 2016-08-08 PH PH12016501570A patent/PH12016501570B1/en unknown
-
2017
- 2017-05-10 US US15/591,605 patent/US9926297B2/en active Active
-
2018
- 2018-02-22 US US15/902,537 patent/US10196380B2/en active Active
- 2018-09-27 CY CY181100996T patent/CY1120834T1/el unknown
- 2018-12-12 US US16/217,570 patent/US10385039B2/en active Active
-
2019
- 2019-02-01 JP JP2019017086A patent/JP6774513B2/ja active Active
- 2019-03-07 AU AU2019201579A patent/AU2019201579B2/en active Active
- 2019-07-01 US US16/459,179 patent/US10689368B2/en active Active
-
2020
- 2020-06-17 US US16/904,099 patent/US10961225B2/en active Active
- 2020-10-05 JP JP2020168341A patent/JP2021006571A/ja not_active Withdrawn
- 2020-11-26 AU AU2020277225A patent/AU2020277225A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060030A patent/JP7652829B2/ja active Active
- 2023-05-02 JP JP2023076025A patent/JP7652833B2/ja active Active
- 2023-05-02 JP JP2023076024A patent/JP7652832B2/ja active Active
-
2025
- 2025-03-14 JP JP2025041135A patent/JP2025085736A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019077725A5 (https=) | ||
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| RU2492167C2 (ru) | Производные аминотриазола в качестве агонистов alх | |
| RU2220142C2 (ru) | Ароматические гетероциклические соединения как противовоспалительные средства | |
| JP4638355B2 (ja) | チアゾール誘導体 | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| EA005680B1 (ru) | Ингибиторы гиразы и их применение для лечения бактериальной инфекции | |
| JP2013516415A5 (https=) | ||
| JP2014511869A5 (https=) | ||
| WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
| JP2011503166A5 (https=) | ||
| JP2007505091A5 (https=) | ||
| JP2016164184A5 (https=) | ||
| JP2026507590A (ja) | 複素環式ｇｌｐ－１アゴニスト | |
| RU2014142598A (ru) | Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в | |
| BG107959A (bg) | Заместени производни на триазол диамин като киназни инхибитори | |
| JP2010533158A5 (https=) | ||
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| KR102655318B1 (ko) | 치환된 질소 함유 화합물 | |
| RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
| JP2003525872A5 (https=) | ||
| HRP20160421T1 (hr) | Derivat azola | |
| JP2019505595A5 (https=) | ||
| JPWO2021170109A5 (https=) | ||
| JP2021535137A5 (https=) |